XTX Topco Ltd Invests $673,000 in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

XTX Topco Ltd purchased a new position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 16,805 shares of the company’s stock, valued at approximately $673,000.

Other institutional investors also recently added to or reduced their stakes in the company. Vanguard Personalized Indexing Management LLC boosted its position in Ionis Pharmaceuticals by 3.5% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 7,624 shares of the company’s stock valued at $363,000 after buying an additional 261 shares during the period. Nicollet Investment Management Inc. boosted its holdings in shares of Ionis Pharmaceuticals by 1.5% in the third quarter. Nicollet Investment Management Inc. now owns 20,402 shares of the company’s stock valued at $817,000 after purchasing an additional 294 shares during the period. Amalgamated Bank grew its stake in Ionis Pharmaceuticals by 3.1% in the third quarter. Amalgamated Bank now owns 9,957 shares of the company’s stock worth $399,000 after purchasing an additional 300 shares in the last quarter. GAMMA Investing LLC raised its position in Ionis Pharmaceuticals by 83.9% during the 3rd quarter. GAMMA Investing LLC now owns 664 shares of the company’s stock valued at $27,000 after purchasing an additional 303 shares in the last quarter. Finally, Itau Unibanco Holding S.A. lifted its holdings in shares of Ionis Pharmaceuticals by 40.9% in the 3rd quarter. Itau Unibanco Holding S.A. now owns 1,081 shares of the company’s stock worth $43,000 after buying an additional 314 shares during the period. Hedge funds and other institutional investors own 93.86% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on IONS. Piper Sandler cut their price target on Ionis Pharmaceuticals from $65.00 to $62.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th. StockNews.com lowered shares of Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, November 12th. JPMorgan Chase & Co. increased their price objective on shares of Ionis Pharmaceuticals from $50.00 to $55.00 and gave the company a “neutral” rating in a research note on Monday, August 26th. Wells Fargo & Company reduced their price objective on shares of Ionis Pharmaceuticals from $82.00 to $77.00 and set an “overweight” rating for the company in a research note on Thursday, November 7th. Finally, Guggenheim dropped their target price on Ionis Pharmaceuticals from $70.00 to $65.00 and set a “buy” rating on the stock in a research report on Wednesday, October 9th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Ionis Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $60.65.

Insider Transactions at Ionis Pharmaceuticals

In related news, CEO Brett P. Monia sold 6,630 shares of Ionis Pharmaceuticals stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $38.05, for a total transaction of $252,271.50. Following the completion of the sale, the chief executive officer now owns 167,393 shares of the company’s stock, valued at $6,369,303.65. The trade was a 3.81 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Eric Swayze sold 1,194 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $37.92, for a total value of $45,276.48. Following the completion of the sale, the executive vice president now owns 33,713 shares in the company, valued at approximately $1,278,396.96. This represents a 3.42 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 7,877 shares of company stock worth $299,578. Company insiders own 2.71% of the company’s stock.

Ionis Pharmaceuticals Stock Down 2.6 %

NASDAQ:IONS opened at $37.01 on Friday. The company has a current ratio of 8.91, a quick ratio of 8.82 and a debt-to-equity ratio of 1.86. Ionis Pharmaceuticals, Inc. has a twelve month low of $33.33 and a twelve month high of $54.44. The company has a market cap of $5.84 billion, a PE ratio of -15.17 and a beta of 0.35. The company’s 50 day moving average is $37.54 and its two-hundred day moving average is $42.29.

Ionis Pharmaceuticals Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.